Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.

ABSTRACT: Identification of the appropriate combination of radionuclide, target and targeting vehicle is critical for successful radioimmunotherapy. For the treatment of disseminated peritoneal diseases such as pancreatic or ovarian cancer, α-emitting radionuclides have been proposed for targeted radiation therapy. This laboratory has taken a systematic approach investigating targeted α-radiation therapy, allowing comparisons to now be made between ²¹¹At, ²²⁷Th, ²¹³Bi and ²¹²Pb. Herein, trastuzumab radiolabeled with ²¹¹At and ²²⁷Th was evaluated for therapeutic efficacy in the LS-174T i.p. tumor model. A dose escalation study was conducted with each radioimmunoconjugate (RIC). Therapeutic benefit was realized with ²¹¹At-tra

SUBMITTER: Milenic DE 

PROVIDER: S-EPMC5664163 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature